This review looked at whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve non-alcoholic fatty liver disease (NAFLD) for people with type 2 diabetes (T2D). It found that these medications can improve liver function in these patients.

This study explored the effects of different second-line therapies combined with metformin (Glucophage) in patients with type 2 diabetes (T2D). The data showed that metformin combinations with a sulfonylurea (SU) had the lowest weight loss, the smallest effect of lowering blood glucose, and an overall, reduced health status.

This study looked at remote screening for diabetic retinopathy (DR; eye disease) in a Japanese population. This study showed that remote screening for DR is an effective way of identifying patients who need ophthalmic intervention.

This study looked at 8 glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes (T2D). They found that all 8 were more effective than placebo and there were no significant differences in safety.

This study analyzed the effectiveness of pioglitazone (Actos) in patients with prediabetes or type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD). The authors concluded that pioglitazone can significantly improve liver function in these patients.

This study compared the effectiveness and tolerance of metformin (Glucophage) extended-release (MXR) and conventional metformin immediate-release (MIR) in adults with type 2 diabetes (T2D). The authors concluded that MIR had better glucose control while MXR but reduced gastrointestinal (GI) side effects.

This review looked at whether medications similar to the GLP-1 hormone can improve liver health for people with type 2 diabetes (T2D) and fatty liver disease. It found that these medications can improve liver health and reduce fat in the liver.

This study looked at how weekly semaglutide (Ozempic) affected patients with type 2 diabetes (T2D) in a real-world setting. It found that semaglutide improved blood sugar control compared to the treatments patients were already taking.

This study examined the effectiveness of adding henagliflozin (SHR3824) to metformin (Glucophage) in patients with uncontrolled type 2 diabetes (T2D). The authors concluded that the addition of 5 mg or 10 mg of henagliflozin to metformin was well-tolerated and effective in these patients. 

This study compared the risk of hypoglycemia (dangerously low blood glucose levels) for insulin glargine 300 U/ml (Gla-300; Toujeo) and standard-of-care basal insulin (SOC-BI) at patients with type 2 diabetes (T2D) with risk factors for hypoglycemia. It found that Gla-300 was associated with a lower risk of hypoglycemia than SOC-BI.